Thoroughbred Financial Services LLC Buys 102 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Thoroughbred Financial Services LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 592 shares of the biopharmaceutical company’s stock after buying an additional 102 shares during the period. Thoroughbred Financial Services LLC’s holdings in Regeneron Pharmaceuticals were worth $421,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth about $36,000. Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $36,000. Finally, Private Wealth Management Group LLC grew its position in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 6.1 %

NASDAQ:REGN opened at $573.45 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $565.36 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market cap of $62.69 billion, a PE ratio of 14.98, a P/E/G ratio of 2.34 and a beta of 0.44. The firm’s 50 day simple moving average is $676.70 and its 200 day simple moving average is $776.59.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $11.86 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on REGN shares. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research report on Monday, March 31st. Bank of America reiterated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. TD Cowen cut their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Finally, UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.